Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust

Omalizumab is a monoclonal antibody against IgE, nowadays approved for the treatment of persistent severe (EU) or moderate-to severe (USA) IgE-mediated asthma but there is also some evidence (case reports and four published clinical trials) on the effectiveness of this medication in urticaria and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kupryś-Lipińska, Izabela, Korczyńska, Paulina, Tworek, Damian, Kuna, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952055/
https://www.ncbi.nlm.nih.gov/pubmed/24683397
http://dx.doi.org/10.5114/pdia.2014.40659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952055/
https://www.ncbi.nlm.nih.gov/pubmed/24683397
http://dx.doi.org/10.5114/pdia.2014.40659

Ejemplares similares